|
|
|
|
|
28.08.26 - 08:00
|
Genetic Analysis AS: Publication of Half-year report 2026 (Cision)
|
|
|
OSLO, NORWAY - August 28, 2026: Genetic Analysis AS ("GA" or the "Company") hereby publishes the half-year report for H1, and April - June 2026. The Half-year report is available as an attached file to this release and on the Company's website. Below is a summary of the report.
Ronny Hermansen, CEO of Genetic Analysis, comments:
“We continued to make good progress in the second quarter, with GA-map® reagent kit sales growing at constant currencies and the new diagnostic marker GA-map® IBD Precision Dx moving closer to its planned RUO launch later this year. We have also strengthened the...
|
|
|
|
|
|
|
27.08.26 - 07:06
|
Oncoinvent presents first half 2026 results (Cision)
|
|
|
Oslo, Norway, 27 August 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its first half 2026 results.
Presentation:
Oncoinvent's management will give an online presentation to investors, analysts and the press at 10:00am CEST today. It will be possible to submit questions during the presentation.
· Presenters: CEO Oystein Soug, CFO Ramzi Amri
· Time: 10:00am CEST
· Webcast link: https://qcnl.tv/p/...
|
|
|
27.08.26 - 07:06
|
Arctic Bioscience – Strong revenue growth and new data on HRO350 complementing the HeROPA trial results (Cision)
|
|
|
Highlights H1 2026:
· Strong sales revenue growth, up 35,2 % compared to last year
· Positive revenue outlook for the remainder of 2026
· Improved adjusted EBITDA year to date in 2026, NOK -12,1 million (NOK -13,6 million)
· Clinical and pre-clinical data on HRO350 published in several peer-reviewed journals and at international conferences
· Positive dialogues with several potential HRO350 partners conducted, focus on next steps
· New long-term financing of NOK 15 million secured in H1-2026
In the first half of 2026, sales development for Arctic Bioscience's...
|
|
|
27.08.26 - 07:06
|
Lytix Biopharma Q2 2026: Marking Defining Milestone (Cision)
|
|
|
Oslo, Norway, August 27, 2026 – Lytix Biopharma ASA (“Lytix” or the “Company”) today reported second quarter and first half 2026 results, highlighted by a defining regulatory milestone: No objection from the U.S. Food and Drug Administration (FDA) on the registrational study design for ruxotemitide in combination with pembrolizumab in high-risk resectable melanoma, removing a key source of uncertainty on the path to full approval.
The FDA feedback, announced in a separate release earlier today, marks a major milestone in the ruxotemitide program and gives Lytix a clear regulatory pathway...
|
|
|
27.08.26 - 07:01
|
FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma (Cision)
|
|
|
Oslo, Norway, August 27, 2026 – Lytix Biopharma ASA (“Lytix” or the “Company”), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced feedback from its July meeting with the U.S. Food and Drug Administration (FDA) on the planned registrational trial of ruxotemitide (LTX-315) in combination with pembrolizumab in high-risk resectable melanoma.
The FDA raised no objection to Lytix's proposed randomized Phase III trial of neoadjuvant ruxotemitide plus pembrolizumab versus pembrolizumab alone, with event-free survival (EFS) as the primary...
|
|
|
26.08.26 - 17:48
|
Lytix to Partner with Leading Investigator on ALETTA Study Testing Ruxotemitide in Combination with Ipilimumab and Nivolumab in Early-stage Resectable Melanoma (Cision)
|
|
|
Investigator-led study by Prof. Christian Blank, could deliver the first clinical validation of ruxotemitide beyond pembrolizumab, complementing the company's registrational path
Oslo, Norway, August 26, 2026 - Lytix Biopharma ASA ("Lytix" or "the Company"), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announces its collaboration in a new investigator-initiated Phase II study in melanoma (ALETTA) in Europe
The study, led by Prof. Christian Blank, MD, PhD, will investigate ruxotemitide (formerly LTX-315) in combination with ipilimumab plus...
|
|
|
|
|
25.08.26 - 10:18
|
Observe Medical ASA: First half year 2026 interim report (Cision)
|
|
|
Oslo, August 25, 2026 - Observe Medical ASA ("the Company" or "Observe Medical") today publishes its financial report for the first half of 2026.
Operating revenues grew 27.4% year-over-year to NOK 14.4 million, driven by increased sales volumes across the UnoMeter™ portfolio, while the gross margin improved to 29.5%. The balance sheet was materially strengthened following the 2025 debt restructuring and the wind-down of Biim Ultrasound, lifting the equity ratio from 2.8% to 31.7%.
Highlights – first half 2026 (unaudited, H1 2025 in brackets)
· Operating revenues of NOK 14.4...
|
|
|
|
|
|
|
21.08.26 - 09:01
|
Lytix Biopharma: Invitation to the Q2 2026 Results Presentation (Cision)
|
|
|
Oslo, Norway, August 20, 2026 – Lytix Biopharma ASA (“Lytix” or the “Company”) will release its second quarter 2026 financial results on Thursday, August 27th, 2026.
Join us for a live webcast presentation featuring CEO Øystein Rekdal, CFO Gjest Breistein, CBO Timothy Herpin, and CMO Karim Benhadji where they will present the quarterly update and provide key insights.
Date: Thursday, August 27th, 2026
Time: 14:00 CET
Q&A Session:
We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A session following...
|
|
|
21.08.26 - 08:01
|
Genetic Analysis Announces First Australian Placement of the GA-map® Dysbiosis Test at Centre for Digestive Diseases in Sydney (Cision)
|
|
|
Oslo, Norway / Sydney, Australia – 21.08.2026: Genetic Analysis AS (GA), a leader in microbiome diagnostics and developer of the GA-map® Dysbiosis Test, today announces the launch of its technology at the Centre for Digestive Diseases (CDD) in Sydney, Australia. The implementation marks the first placement of GA's microbiome testing technology in Australia, representing a significant milestone in the company's international expansion strategy.
The Centre for Digestive Diseases is internationally recognized for its expertise in gastrointestinal disorders and is a pioneer in the use of fecal...
|
|
|
20.08.26 - 15:01
|
Clinical article has been accepted for publication - UnoMeter[TM] Safeti[TM] Max (Cision)
|
|
|
Oslo, 20 August 2026 - Observe Medical ASA (the "Company" or "Observe Medical") is pleased to announce that an article with clinical relevant data related to the Company's UnoMeter[TM] Safeti[TM] Max has been accepted for publication by Journal of the Healthcare Infection Society (https://www.his.org.uk/): Infection Prevention in Practice (IPIP), an open access companion title to the respected Journal of Hospital Infection (https://www.journals.elsevier.com/journal-of-hospital-infection), in Journal of Hospital Infection.
The article “Evaluation of retrograde bacterial migration in a...
|
|
|
|
|
|
|
|
|
20.08.26 - 09:12
|
Arctic Bioscience – Invitation to presentation of half year 2026 results (Cision)
|
|
|
Arctic Bioscience will publish its financial results for the first half year of 2026 on Thursday 27[th] of August, at 07:00 CET.
The same day at 10:00 CET, the Company will host a webcast to present the results and give an operational update. Following the presentation, it will be opened for questions from the audience.
Webcast details:
Date: Thursday 27[th] of August 2026
Time: 10:00 CET
Format: Webcast and Q&A
Language: Norwegian/English
The presentation can be accessed with the link below:
https://events.teams.microsoft.com/event/6617e53e-29a2-4cf4-ad29-d999e4d3944d@...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
